Caligan Partners LP: ADMA BIOLOGICS INC (ADMA): Quarterly 13F Position History
As of Q2 2026, Caligan Partners LP reported 5,725,007 shares of ADMA BIOLOGICS INC (ADMA), worth $47.9M and representing 2.3% of its 13F equity book. Quarter-over-quarter share count change: + 968,496 (+20.4%) . The position first appeared in Q4 2022 and has been disclosed across 15 13F-HR filings in Pactolio's tracked window.
- 5,725,007Shares Held (Latest Filing)
- $47.9MReported Market Value (Latest Filing)
- 2.3%Portfolio Weight (% of 13F Equity Book)
- +968,496Quarter-over-Quarter Share Change
- +$5.1MQuarter-over-Quarter Value Change
- 5,725,007Peak Reported Shares (Historical)
Quarterly 13F-HR Disclosure History Source: SEC 13F-HR filings, 15 quarter s
| Quarter | Shares | QoQ Share Change | Share Change (%) | Market Value | Weight | Implied Price |
|---|---|---|---|---|---|---|
| Q2 2026 | 5,725,007 | +968,496 | +20.4% | $47.9M | 2.3% | $8.4 |
| Q1 2026 | 4,756,511 | +1,744,003 | +57.9% | $42.9M | 3.0% | $9.0 |
| Q4 2025 | 3,012,508 | +375,899 | +14.3% | $54.9M | 5.0% | $18.2 |
| Q3 2025 | 2,636,609 | +2,636,609 | – | $38.7M | 5.4% | $14.7 |
| Q2 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2025 | 0 | 0 | – | $0 | 0.0% | – |
| Q4 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q3 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q2 2024 | 0 | 0 | – | $0 | 0.0% | – |
| Q1 2024 | 0 | 473,087 | -100.0% | $0 | 0.0% | – |
| Q4 2023 | 473,087 | 124,426 | -20.8% | $2.1M | 0.7% | $4.5 |
| Q3 2023 | 597,513 | 250,000 | -29.5% | $2.1M | 1.1% | $3.6 |
| Q2 2023 | 847,513 | 815,100 | -49.0% | $3.1M | 1.9% | $3.7 |
| Q1 2023 | 1,662,613 | 1,013,480 | -37.9% | $5.5M | 3.8% | $3.3 |
| Q4 2022 | 2,676,093 | – | – | $10.4M | 8.2% | $3.9 |
Methodology & FAQ
How This Position History Is Sourced
Each row is one SEC Form 13F-HR filing disclosing this position. Share count, market value, and reported quarter are taken verbatim from the filing; portfolio weight is recomputed against the same filing's total reported equity book. Implied price-per-share is market value divided by shares, a quarter-end mark rather than the manager's cost basis. See the full methodology document for the normalization rules.
When did Caligan Partners LP first disclose a ADMA position in 13F-HR filings?
Caligan Partners LP first reported ADMA BIOLOGICS INC (ADMA) on its 13F-HR filing for the period ending 2022-12-31 (Q4 2022). The position has appeared on 15 reported quarters within Pactolio's tracked window.
What was Caligan Partners LP's most recent quarter-over-quarter share-count change in ADMA?
Between Q1 2026 and Q2 2026, Caligan Partners LP added 968,496 shares of ADMA (+20.4%), bringing the total reported position to 5,725,007 shares at a market value of $47.9M.
Does the implied price-per-share represent Caligan Partners LP's cost basis in ADMA?
No. The implied price-per-share column is the 13F-HR reported market value divided by reported share count on the filing date (end of quarter). It is a quarter-end mark, not a cost basis or transaction price. Use it as a sanity check on the value column, not as an indicator of the manager's entry or exit price.